ArticleCancer imaging : the official publication of the International Cancer Imaging Society2021
Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Prognostic impact of interstitial lung abnormalities in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Fibrotic Interstitial Lung Abnormalities on Preoperative CT Images Predict Cause-Specific Mortality after Stage I Non-Small Cell Lung Cancer Resection.Annals of surgical oncology · 2026Article
- Wnt3-mediated fibrosis and carcinogenesis of lung squamous cell carcinoma in idiopathic pulmonary fibrosis.iScience · 2026Article
- Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.NPJ digital medicine · 2026Article
- Automated interstitial lung abnormalities detection at CT: external validation and potential recognition of traction bronchiectasis/bronchiolectasis.Japanese journal of radiology · 2026Article
- Progression of interstitial lung abnormalities and its impact on mortality in patients with lung cancer resection.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Association of automated quantified emphysema and interstitial lung abnormality with survival in non-small cell lung cancer.Insights into imaging · 2026Article
- Current diagnosis, epidemiology, and management of interstitial lung abnormalities.Frontiers in medicine · 2026Review
- Study of non-surgical therapeutic patterns and prognosis in elderly patients with stage II non-small-cell lung cancer: an investigational study based on the SEER database.Translational cancer research · 2025Article
- Impact of Quantitatively Assessed Interstitial Lung Abnormalities on Long-Term Outcomes After Lung Cancer Surgery.Journal of clinical medicine · 2025Article
- Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.Translational lung cancer research · 2025Article
- Interstitial Lung Abnormalities: Unraveling the Journey from Incidental Discovery to Clinical Significance.Diagnostics (Basel, Switzerland) · 2025Review
- Automated chest CT three-dimensional quantification of body composition: adipose tissue and paravertebral muscle.Scientific reports · 2024Article
- Interstitial lung abnormality in COPD is inversely associated with the comorbidity of lung cancer.BMC pulmonary medicine · 2024Observational
- Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities.Cancer immunology, immunotherapy : CII · 2024Article
- Endobronchial Optical Coherence Tomography as a Novel Method forAmerican journal of respiratory and critical care medicine · 2024Article
- Automated Interstitial Lung Abnormality Probability Prediction at CT: A Stepwise Machine Learning Approach in the Boston Lung Cancer Study.Radiology · 2024Article
- Association between interstitial lung abnormality and mortality in patients with esophageal cancer.Japanese journal of radiology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundInterstitial lung abnormalities (ILA) can be detected on computed tomography (CT) in lung cancer patients and have an association with mortality in advanced non-small cell lung cancer (NSCLC) patients. The aim of this study is to demonstrate the significance of ILA for mortality in patients with stage I NSCLC using Boston Lung Cancer Study cohort.
methodsTwo hundred and thirty-one patients with stage I NSCLC from 2000 to 2011 were investigated in this retrospective study (median age, 69 years; 93 males, 138 females). ILA was scored on baseline CT scans prior to treatment using a 3-point scale (0 = no evidence of ILA, 1 = equivocal for ILA, 2 = ILA) by a sequential reading method. ILA score 2 was considered the presence of ILA. The difference of overall survival (OS) for patients with different ILA scores were tested via log-rank test and multivariate Cox proportional hazards models were used to estimate hazard ratios (HRs) including ILA score, age, sex, smoking status, and treatment as the confounding variables.
resultsILA was present in 22 out of 231 patients (9.5%) with stage I NSCLC. The presence of ILA was associated with shorter OS (patients with ILA score 2, median 3.85 years [95% confidence interval (CI): 3.36 - not reached (NR)]; patients with ILA score 0 or 1, median 10.16 years [95%CI: 8.65 - NR]; P < 0.0001). In a Cox proportional hazards model, the presence of ILA remained significant for increased risk for death (HR = 2.88, P = 0.005) after adjusting for age, sex, smoking and treatment.
conclusionsILA was detected on CT in 9.5% of patients with stage I NSCLC. The presence of ILA was significantly associated with a shorter OS and could be an imaging marker of shorter survival in stage I NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.